MetaCap

Greenland Mines (GRML) vs OKYO Pharma (OKYO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OKYO Pharma (OKYO) has outperformed Greenland Mines (GRML) over the past year, losing 49.5% versus a loss of 87.1%. OKYO Pharma is the larger company by market cap ($56.2 million vs $44.3 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRML-87.08%OKYO-49.53%
+53%-20%-94%
Nov 21, 20251 yearNov 20, 2026
GRML-99.39%OKYO-64.33%
+33%-36%-106%
May 16, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRML versus OKYO key metrics
MetricGRMLOKYO
Share price$2.99$1.07
Market cap$44.31M$56.15M
1-day change+2.75%-7.76%
YTD return-79.31%-48.31%
1-year return-87.08%-49.53%
EPS (TTM)$-9.74$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-10.55M$-4.71M
52-week high$37.00$3.20
52-week low$2.75$1.00
Distance from 52-week high-91.92%-66.56%
Analyst consensusnonestrong_buy
Avg. price target upside+3578.93%+678.50%
Average volume8.93M143.41K
Shares outstanding14.82M52.48M
Employees55
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKYO has outperformed GRML by 37.6 percentage points over the past year.

About Greenland Mines

GRML stock →

Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

About OKYO Pharma

OKYO stock →

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

GRML vs OKYO FAQ

Which is bigger, Greenland Mines or OKYO Pharma?

OKYO Pharma (OKYO) is larger, with a market capitalization of $56.15M compared with $44.31M for Greenland Mines (GRML).

Which stock has performed better over the past year, GRML or OKYO?

OKYO returned -49.53% over the past 12 months, compared with -87.08% for GRML (price return, excluding dividends). Past performance does not predict future results.

Are Greenland Mines and OKYO Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons